

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Use of a A method for increasing the number of islets of Langerhans cells, treatment of prediabetes, treatment or prevention of insulin-dependent diabetes, prevention of non-insulin-dependent diabetes, or treatment of early non-insulin-dependent diabetes, comprising administering to a patient in need thereof an effective amount of a kynurene 3-hydroxylase inhibitor for the manufacture of a medicament for increasing the number of islets of Langerhans cells.~~
2. (Currently Amended) ~~Use of a kynurene 3-hydroxylase inhibitor A method according to Claim 1, wherein in increasing the number of islets of Langerhans cells, the patient is in need of in the context of the treatment and/or or prevention of diabetes, its complications and/or its or a complication thereof or a related pathologies pathology thereof.~~
3. (Currently Amended) ~~Use of a kynurene 3-hydroxylase inhibitor for the manufacture of a medicament A method according to claim 1, which is for the treatment of prediabetes.~~
4. (Currently Amended) ~~Use A method according to Claim 3, for which the wherein said prediabetes is an insulin-dependent prediabetes.~~
5. (Currently Amended) ~~Use A method according to Claim 3, for which the wherein said prediabetes is a non-insulin-dependent prediabetes.~~
6. (Currently Amended) ~~Use of a kynurene 3-hydroxylase inhibitor for the manufacture of a medicament for the A method according to claim 1, which is for the treatment and/or or prevention of insulin-dependent diabetes.~~
7. (Currently Amended) ~~Use of a kynurene 3-hydroxylase inhibitor for the manufacture of a medicament A method according to claim 1, which is for the prevention of non-insulin-dependent diabetes.~~

8. (Currently Amended) Use of a kynureine 3-hydroxylase inhibitor for the manufacture of a medicament A method according to claim 1, which is for the treatment of early non-insulin-dependent diabetes.

9. (Currently Amended) Use A method according to claim 3, for which the said treatment or prevention is by increasing wherein the number of islets of Langerhans cells are increased.

10. (Currently Amended) Use of a kynureine 3-hydroxylase inhibitor in combination with one or more immunosuppressants, for the manufacture of a medicament A method according to claim 1, which is for the prevention and/or or treatment of insulin-dependent diabetes, further comprising administering an immunosuppressant.

11. (Currently Amended) Use A method according to claim 1, which is suitable for the said treatment and/or the said prevention in the case of a wherein the patient with has an impairment in the number of islets of Langerhans cells.

12. (Currently Amended) Use A method according to Claim 11, for which the wherein said patient shows a decrease in the number of islets of Langerhans cells of at least 40%.

13. (Currently Amended) Use A method according to Claim 11, for which the wherein said patient shows a decrease in the number of islets of Langerhans cells of between 50% and to 90%.

14. (Currently Amended) Use A method according to claim 1, wherein the which is suitable for the said treatment and/or the said prevention in the case of a patient with has glucose intolerance.

15. (Currently Amended) Use A method according to Claim 14, for which the wherein said patient presents a fasting glycaemia of between 1.10 g/l and to 1.26 g/l and a glycaemia after meals a meal of between 1.40 g/l and to 2 g/l-after meals.

16. (Currently Amended) Use A method according to claim 1, which is suitable for the said treatment and/or the said prevention in the case of a wherein the patient with has one or more anti-islets of Langerhans cells immunological markers.

17. (Currently Amended) Use A method according to Claim 16, ~~for which the~~ wherein said marker(s) indicate(s) the existence of an autoimmune response of the body directed against the antigenic markers of the body's islets of Langerhans cells.

18. (Currently Amended) Use A method according to Claim 16, ~~for which the~~ wherein said marker(s) is (are) ~~chosen from the~~ anti-islet (ICA), anti-glutamic acid decarboxylase (GAD), anti-tyrosine phosphatase (IA-2) ~~and~~ or anti-(pro)insulin (AIA) auto-antibodies, or the anti-carboxypeptidase H, anti-64kD ~~and~~ or anti-heat shock protein antibodies.

19. (Currently Amended) Use A method according to claim 1, ~~which is suitable for the said treatment and/or the said prevention in the case of a~~ wherein the patient ~~with~~ has insulin resistance.

20. (Currently Amended) Use A method according to Claim 19, ~~for which the~~ wherein said patient responds partially or not at all to insulin secreted by the beta cells or injected.

21. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said patient presents a level of glycated haemoglobin of higher than 7%.

22. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said patient has islets of Langerhans cells showing an anomaly of insulin secretion in response to glucose.

23. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said patient presents a suppression of the early peak of insulin secretion.

24. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said patient shows related hyperglycaemia and obesity.

25. (Currently Amended) Use A method according to Claim 24, ~~for which the~~ wherein said patient suffers from paediatric obesity.

26. (Currently Amended) Use A method according to claim 1, ~~which is suitable for the said treatment and/or the said prevention in the case of a wherein the patient presenting any has a~~ diabetic risk factor.



27. (Currently Amended) Use A method according to Claim 25, ~~for which the wherein~~ said risk factor is ~~chosen from~~ familial history, gestational diabetes, excess weight, obesity, insufficient physical exercise, high blood pressure, a high level of triglycerides, hyperlipidaemia and or inflammation.

28. (Currently Amended) Use A method according to claim 1, comprising the in vitro treatment of isolated islets of Langerhans cells with ~~the~~ said kynurenine 3-hydroxylase inhibitor.

29. (Currently Amended) Process A process for increasing the number or the insulin-secreting capacity of islets of Langerhans cells, comprising the in vitro application of a kynurenine 3-hydroxylase inhibitor to ~~the~~ said cells.


30-32. (Cancelled)


33. (Currently Amended) Use A method according to claim 1, ~~for which the wherein~~ said kynurenine 3-hydroxylase inhibitor is a compound of the general formula (I) or (II):



in which:

- W represents a divalent radical ~~chosen from the following radicals:~~





- R^1 represents a ~~radical chosen from~~ linear or branched alkyl containing ~~from~~ 1 to 14 carbon atoms ~~and or an~~ optionally substituted, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, a heterocyclic radical, an aryl radical ~~and or~~ a heteroaryl radical;

- R^2 is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, carboxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylcarbonyl, alkoxy carbonyl, aryl, heteroaryl, cycloalkyl ~~and or~~ a heterocyclic radical;

- R^3 is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, cycloalkyl ~~and or~~ a heterocyclic radical;

- R^2 and R^3 together ~~also possibly forming a group~~ ~~optionally form~~ $=CR^{16}R^{17}$; or alternatively together ~~forming~~ ~~form~~, with the carbon atom that bears them, a cycloalkyl radical or a heterocyclic radical;

- R^4 is ~~chosen from~~ hydroxyl, alkoxy, alkenyloxy, alkynyoxy, aryloxy, heteroaryloxy, $-N(R^{12}R^{12'})$, $-N(R^{12})OR^{13}$, linear or branched alkyl containing ~~from~~ 1 to 14 carbon atoms ~~and or an~~ optionally substituted, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl ~~and or~~ a heterocyclic radical;

- R^5 , R^6 , R^7 and R^8 , which may be identical or different, are ~~chosen~~, independently of each other, ~~from~~ hydrogen, a halogen atom, ~~and or~~ a nitro, cyano, hydroxyl, trifluoromethyl, alkyl, alkoxy, cycloalkyl or aryl radical;

- the radicals R^5 and R^6 , ~~on the one hand~~, or R^6 and R^7 , ~~on the other hand~~, may also form, together with the carbon atoms to which they are attached, a benzene ring optionally substituted by one or more groups, which may be identical or different, ~~chosen from and are~~ a halogen atom, a trifluoromethyl, cyano or nitro radical, an alkyl radical ~~and or~~ an alkoxy radical;

- R^9 represents hydrogen or an alkyl radical;

- R^{10} is ~~chosen from~~ an alkyl, an aryl ~~and or~~ a heteroaryl radical;

- R^{12} and $R^{12'}$, which may be identical or different, are ~~chosen~~, independently of each other, ~~from~~ hydrogen ~~and or~~ an alkyl, alkenyl, alkynyl, alkylcarbonyl, aryl or heteroaryl radical; or alternatively R^{12} and $R^{12'}$ may form, together with the nitrogen atom to which they are attached, a monocyclic or bicyclic heterocyclic group containing a total of 5 to 10 atoms, among which 1, 2, 3 or 4 are ~~chosen~~, independently of each other, ~~from~~ nitrogen, oxygen ~~and or~~ sulfur,

the said heterocyclic radical also optionally comprising 1, 2, 3 or 4 double bonds and optionally being substituted by one or more ~~chemical~~ groups, which may be identical or different, ~~chosen from and are~~ hydroxyl, halogen atom, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, heterocyclic radical ~~and or~~ trifluoromethyl;

- R^{13} is ~~chosen from~~ hydrogen ~~and or~~ an alkyl, alkenyl, alkynyl, aryl, heteroaryl, - $N(R^{12}R^{12})$ or $-N(R^{12})OR^{13}$ radical;

- R^{14} is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, carboxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylcarbonyl, alkoxy carbonyl, aryl, arylalkyl, heteroaryl, cycloalkyl ~~and or~~ a heterocyclic radical;

- R^{14} may also form a bond with R^2 , thus forming a double bond between the carbon atoms respectively bearing the substituents R^{14} and R^2 ; or alternatively R^{14} forms, with R^2 and with the carbon atoms that bear them, a ring containing a total of 3, 4, 5, 6 or 7 carbon atoms, among which 1, 2 or 3 may be replaced with ~~an atom chosen from~~ nitrogen, oxygen ~~and or~~ sulfur, the said ring ~~possibly~~ optionally comprising one or more unsaturations in the form of (a) double bond(s), and being optionally substituted by one or more radicals, which may be identical or different, ~~chosen from and are~~ oxo, alkoxy, alkoxy carbonyl ~~and or~~ alkylcarbonyloxy;

- R^{15} is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, carboxyl, alkyl, alkenyl, alkynyl, alkylcarbonyl, alkoxy carbonyl, alkoxy, alkenyloxy, alkynyoxy, aryloxy, cycloalkyloxy, heteroaryloxy, heterocyclyloxy, alkylthio, alkenylthio, alkynylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclthio, aryl, heteroaryl, cycloalkyl ~~and or~~ a heterocyclic radical;

- R^{14} and R^{15} ~~also possibly forming~~ optionally form, together with the carbon atom that bears them, a cycloalkyl radical or a heterocyclic radical;

- R^{16} and R^{17} , which may be identical or different, are ~~chosen~~, independently of each other, ~~from~~ hydrogen, a halogen atom, an alkyl, aryl, heteroaryl or cycloalkyl radical ~~and or~~ a heterocyclic radical; or alternatively

- R^{16} and R^{17} form, together with the carbon atom that bears them, a cycloalkyl radical or a heterocyclic radical; and

- R^{11} is ~~chosen from~~ hydrogen ~~and or~~ an alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or cycloalkylalkyl radical, ~~and any or a~~ protecting group for an amine function;

~~and also the possible or a geometrical and/or or optical isomers isomer~~ thereof, ~~and possi-~~

ble or a tautomeric forms form thereof;

~~the solvates and hydrates of these compounds; or a solvate or hydrate thereof; or a and also the possible salts salt thereof with a pharmaceutically acceptable acid or base, or alternatively the a pharmaceutically acceptable prodrugs of these compounds prodrug thereof.~~

34-54. (Cancelled)

55. (New) A method according to claim 33, wherein the compound administered is capable of the inhibition of kynurenine 3-hydroxylase.

56. (New) A method according to claim 33, wherein the compound administered is capable of the inhibition of kynurenine 3-hydroxylase in an *in vitro* test.